Product Details:
Interceptor works by destroying heartworm
larvae in the tissue stage and eliminating the adult stage of whipworms,
roundworms, and hookworms. The active ingredient in Interceptor, milbemycin
oxime, interferes with the neurotransmission of the invertebrates.
Interceptor is available by veterinary
prescription.
Interceptor (milbemycin oxime)
Active ingredients:
Interceptor Brown (Dogs 2-10 lbs):
Milbemycin Oxime 2.3 mg
Interceptor Green (Dogs 11-25 lbs,
Cats 1.5-6 lbs): Milbemycin Oxime 5.75 mg
Interceptor Yellow (Dogs 26-50 lbs,
Cats 6.1-12 lbs): Milbemycin Oxime 11.5 mg
Interceptor White (Dogs 51-100 lbs,
Cats 12.1-25 lbs): Milbemycin Oxime 23 mg
Warnings:
Keep this product out of reach of children
and animals. Do not use or store in or near open flame or heat.
Intended for use in dogs and puppies
at least 4 weeks of age and weighing more than 2 lbs, and in cats and
kittens weighing at least 1.5 lbs. that are 6 weeks of age and older.
CAUTION: All animals should
undergo testing for existing heartworm infections before beginning treatment
with Interceptor.
Side effects are not common but may
include vomiting, depression, loss of appetite, hypersalivation, drowsiness,
diarrhea, drowsiness, weakness, and seizures.
Humans in contact with pets infected
with hookworms and roundworms should take every available precaution
and practice good hygiene, as these parasites are transmissible to humans.
Symptoms of overdose are similar to
side effects and include drowsiness, depression, reduced appetite, vomiting,
diarrhea, hypersalivation, seizures, and weakness. Immediately seek
treatment for a known or suspected overdose.
Safety of using this product in breeding,
pregnant, lactating, or heartworm-positive animals has not been established.
Warranty and Manufacturer Information:
U.S. Patent No. 4,547,520
Manufactured for: Novartis Animal Health
US, Inc., Greensboro, NC 27408, USA
NADA #140-915, Approved by FDA
© 2007 Novartis
2003309
NAH/INT-FTCF/VI/2
12/07
INTERCEPTOR and Flavor Tabs are registered
trademarks of Novartis AG.
NAC No.: 11310016